ReviewJournal of gastrointestinal oncology2016
Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others.
Review in Journal of gastrointestinal oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer.Medicine · 2018Trial
- Suppression of the myofibroblastic cancer-associated fibroblast phenotype to enhance anti-PD-1 response.Journal of experimental & clinical cancer research : CR · 2026Article
- KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.Scientific reports · 2024Article
- Exploring the Potential of Humoral Immune Response to CommensalBiomedicines · 2024Review
- Article
- Review
- Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Review
- Article
- Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers-A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.Current oncology (Toronto, Ont.) · 2022Article
- Molecular Pathogenesis of Colorectal Cancer with an Emphasis on Recent Advances in Biomarkers, as Well as Nanotechnology-Based Diagnostic and Therapeutic Approaches.Nanomaterials (Basel, Switzerland) · 2022Review
- The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy.Frontiers in medicine · 2022Review
- The Importance of Being "That" Colorectal pT1: A Combined Clinico-Pathological Predictive Score to Improve Nodal Risk Stratification.Frontiers in medicine · 2022Article
- Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment.Journal of clinical laboratory analysis · 2021Review
- Associations between tissue-based CD3+ T-lymphocyte count and colorectal cancer survival in a prospective cohort of older women.Molecular carcinogenesis · 2021Article
- PEG3 mutation is associated with elevated tumor mutation burden and poor prognosis in breast cancer.Bioscience reports · 2020Article
- Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.Journal for immunotherapy of cancer · 2020Article
- Evaluation of Concordance Between Deficient Mismatch Repair and Microsatellite Instability Testing and Their Association with Clinicopathological Features in Colorectal Cancer.Cancer management and research · 2020Article
- Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response.Molecular and clinical oncology · 2020Article
- A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies.Cancer management and research · 2020Review
- Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Colorectal cancer (CRC) is a heterogeneous disease for which the treatment backbone has primarily been cytotoxic chemotherapy. With better understanding of the involved molecular mechanisms, it is now known that there are a number of epigenetic and genetic events, which are involved in CRC pathogenesis. Specific biomarkers have been identified which can be used to determine the clinical outcome of patients beyond tumor staging and predict for treatment efficacy. Molecular testing is now routinely performed to select for patients that will benefit the most from targeted agents and immunotherapy. In addition to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.